Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA018989 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA018989, RRID:AB_1846681
- Product name
- Anti-CHN2
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human CHN2, Gene description: chimerin 2, Alternative Gene Names: ARHGAP3, RhoGAP3, Validated applications: IHC, Uniprot ID: P52757, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.05 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references VEGF–neuropilin-2 signaling promotes stem-like traits in breast cancer cells by TAZ-mediated repression of the Rac GAP β2-chimaerin
A new role of the Rac-GAP β2-chimaerin in cell adhesion reveals opposite functions in breast cancer initiation and tumor progression
Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility
Elaimy A, Guru S, Chang C, Ou J, Amante J, Zhu L, Goel H, Mercurio A
Science Signaling 2018;11(528)
Science Signaling 2018;11(528)
A new role of the Rac-GAP β2-chimaerin in cell adhesion reveals opposite functions in breast cancer initiation and tumor progression
Casado-Medrano V, Barrio-Real L, García-Rostán G, Baumann M, Rocks O, Caloca M
Oncotarget 2016;7(19):28301-28319
Oncotarget 2016;7(19):28301-28319
Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility
Alvi M, McArt D, Kelly P, Fuchs M, Alderdice M, McCabe C, Bingham V, McGready C, Tripathi S, Emmert-Streib F, Loughrey M, McQuaid S, Maxwell P, Hamilton P, Turkington R, James J, Wilson R, Salto-Tellez M
Oncotarget 2015;6(25):20863-20874
Oncotarget 2015;6(25):20863-20874
No comments: Submit comment
No validations: Submit validation data